Overview

This trial is active, not recruiting.

Condition prostate cancer
Treatment ixabepilone
Phase phase 2
Sponsor Brown University
Collaborator Rhode Island Hospital
Start date February 2009
End date March 2011
Trial size 16 participants
Trial identifier NCT00828308, BMS-CA163-164, BrUOG-Pros-221

Summary

Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.

Prostatectomy 2-8 weeks after completion(standard of care and not a part of study)

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study***
ixabepilone
Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion ***this was standard of care and not a part of the study**

Primary Outcomes

Measure
Prostate-Specific Antigen (PSA) Response
time frame: after 12 weeks of ixabepilone

Eligibility Criteria

Male participants at least 18 years old.

Inclusion Criteria: - Histologic documentation of prostatic adenocarcinoma. Patients with small cell, neuroendocrine or transitional cell carcinomas are not eligible. - All eligible patients must have a known Gleason sum based on biopsy or TURP at the time of registration. - Clinically Localized Disease: Patients must have clinical stage T1-T3a and no radiographic evidence of metastatic disease as demonstrated by: - Either CT or MRI of the abdomen and pelvis, that demonstrate no nodes > 1 cm: or endorectal MRI(If one or more lymph nodes(s) measures > 1 cm, a negative biopsy is required.) - Negative bone scan (with plain films and /or MRI and/or CT scan confirmation, if necessary).(Positive PET and Prostascint scans are not considered proof of metastatic disease.) - Patients must have high risk disease defined as either: - Gleason Score 8-10 - PSA > 15 ng/ml - Stage T3a - Stage T2c and Gleason score of 7 - Stage T2b, Gleason score of 7, greater than 50% of the cores positive from a single lobe. - No prior treatment for prostate cancer including prior surgery (excluding TURP), pelvic lymph node dissection, radiation therapy, chemotherapy or hormone therapy. - Patient must be appropriate candidates for radical prostatectomy with an estimated life expectancy > 10 years as determined by an urologist. - ECOG PS 0-1 - Age > 18 years of age. - Required initial laboratory values: - ANC > 1500/ul - Platelet count > 100,000/mm3 - Creatinine < 2.0 mg/dl - Serum PSA < 100 ng/ml - Bilirubin < upper institutional limit of normal (ULN) - AST/ALT < 2.5 X ULN Exclusion Criteria: - Active or uncontrolled infection. - Patients must not have other coexistent medical condition that would preclude protocol therapy. - Previous severe hypersensitivity reaction to a drug formulated in CremophoreL (polyoxyethylated castor oil). - Grade 1 or greater neuropathy (motor or sensory) at study entry

Additional Information

Official title BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study
Description Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles. Prostatectomy 2-8 weeks after completion of chemotherapy (this was standard of care). This protocol evaluated weekly ixabepilone prior to robotic prostatectomy for patients with high risk localized prostate cancer. PSA response rate, tumor margin status and pathologic responses were assessed.
Trial information was received from ClinicalTrials.gov and was last updated in January 2014.
Information provided to ClinicalTrials.gov by Brown University.